Advertisement vbandhakavi, Author at Pharmaceutical Business review - Page 33 of 53
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by vbandhakavi 

Diurnal secures second US patent for Chronocort

US 10,166,194, entitled “Hydrocortisone Controlled Release Formulation”, is a patent claiming a method of treatment for adrenal dysfunction, including the diseases congenital adrenal hyperplasia (CAH) and adrenal insufficiency

CANbridge, WuXi expand rare disease partnership

These new candidates target rare genetic chronic diseases. According to the agreement, CANbridge has an exclusive regional or global rights for these therapies. WuXi Biologics will receive upfront,

Lilly to acquire Loxo Oncology for $8bn

Loxo Oncology is engaged in the development and commercialization of highly selective drug candidates for patients with genomically defined cancers. The company is developing targeted drugs that are